1. Home
  2. DEC vs ANL Comparison

DEC vs ANL Comparison

Compare DEC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diversified Energy Company plc

DEC

Diversified Energy Company plc

HOLD

Current Price

$14.47

Market Cap

993.4M

Sector

N/A

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.62

Market Cap

998.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DEC
ANL
Founded
2001
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
993.4M
998.8M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
DEC
ANL
Price
$14.47
$10.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
7
Target Price
$20.43
★ $29.50
AVG Volume (30 Days)
★ 545.8K
319.9K
Earning Date
11-04-2026
08-14-2026
Dividend Yield
★ 7.90%
N/A
EPS Growth
★ 311.06
N/A
EPS
★ 1.14
N/A
Revenue
★ $1,829,142,000.00
N/A
Revenue This Year
$24.84
$243.83
Revenue Next Year
$33.22
N/A
P/E Ratio
$12.89
★ N/A
Revenue Growth
★ 141.54
N/A
52 Week Low
$12.35
$0.88
52 Week High
$18.90
$17.25

Technical Indicators

Market Signals
Indicator
DEC
ANL
Relative Strength Index (RSI) 53.40 36.44
Support Level $12.48 $8.96
Resistance Level $14.95 $12.49
Average True Range (ATR) 0.40 1.30
MACD 0.05 -0.29
Stochastic Oscillator 60.87 5.98

Price Performance

Historical Comparison
DEC
ANL

About DEC Diversified Energy Company plc

Diversified Energy Co engaged in the production, transportation, and marketing of natural gas, NGLs, and oil, managing a diversified portfolio of mature, long-life assets located across the United States. The company derives revenues from the sale of oil, natural gas and natural gas liquids.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: